Product
AIN457
Aliases
secukinumab, Secukinumab
Name
COSENTYX
INN Name
secukinumab
FDA Approved
Yes
3 clinical trials
1 organization
4 indications
1 document
Indication
Juvenile Psoriatic ArthritisIndication
Enthesitis Related ArthritisIndication
Psoriatic ArthritisIndication
Ankylosing spondylitisClinical trial
An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related ArthritisStatus: Active (not recruiting), Estimated PCD: 2024-10-03
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic ArthritisStatus: Completed, Estimated PCD: 2022-05-17
Clinical trial
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing SpondylitisStatus: Completed, Estimated PCD: 2021-11-12
Document
DailyMed Label: COSENTYXOrganization
Novartis Pharmaceuticals Corporation